Faron Pharmaceuticals Oy Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Juho Jalkanen
Chief executive officer
€220.5k
Total compensation
| CEO salary percentage | 99.93% |
| CEO tenure | 1yr |
| CEO ownership | n/a |
| Management average tenure | 1yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €221k | €220k | -€26m |
| Sep 30 2024 | n/a | n/a | -€29m |
| Jun 30 2024 | n/a | n/a | -€32m |
| Mar 31 2024 | n/a | n/a | -€31m |
| Dec 31 2023 | €512k | €398k | -€31m |
| Sep 30 2023 | n/a | n/a | -€30m |
| Jun 30 2023 | n/a | n/a | -€29m |
| Mar 31 2023 | n/a | n/a | -€29m |
| Dec 31 2022 | €635k | €539k | -€29m |
| Sep 30 2022 | n/a | n/a | -€26m |
| Jun 30 2022 | n/a | n/a | -€24m |
| Mar 31 2022 | n/a | n/a | -€22m |
| Dec 31 2021 | €450k | €381k | -€21m |
| Sep 30 2021 | n/a | n/a | -€21m |
| Jun 30 2021 | n/a | n/a | -€20m |
| Mar 31 2021 | n/a | n/a | -€19m |
| Dec 31 2020 | €424k | €324k | -€17m |
| Sep 30 2020 | n/a | n/a | -€16m |
| Jun 30 2020 | n/a | n/a | -€14m |
| Mar 31 2020 | n/a | n/a | -€14m |
| Dec 31 2019 | €273k | €257k | -€13m |
| Sep 30 2019 | n/a | n/a | -€13m |
| Jun 30 2019 | n/a | n/a | -€12m |
| Mar 31 2019 | n/a | n/a | -€16m |
| Dec 31 2018 | €361k | €221k | -€20m |
Compensation vs Market: Juho's total compensation ($USD247.85K) is below average for companies of similar size in the German market ($USD917.60K).
Compensation vs Earnings: Juho's compensation has been consistent with company performance over the past year.
CEO
Juho Jalkanen (46 yo)
Dr. Juho Markku Jalkanen, M.D., MSc & Ph D., is Founder of Faron Pharmaceuticals Oy and serves as its Chief Executive Officer and Director since May 1, 2024 and served as its Chief Operating Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 1yr | €220.51k | no data | |
| Chief Financial Officer | 1.1yrs | €455.09k | no data | |
| Chief Scientific Officer | 2.4yrs | no data | no data | |
| General Counsel | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: 4FR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 1yr | €220.51k | no data | |
| Non- Executive Director | 18.6yrs | €532.46k | 2.74% € 8.7m | |
| Board Observer | 6.7yrs | €36.20k | no data | |
| Independent Non-Executive Director | 8yrs | €48.00k | no data | |
| Independent Non-Executive Chairman | 2.2yrs | €62.50k | 0.025% € 81.2k | |
| Non-Executive Director | 1.7yrs | €42.00k | no data | |
| Member of the Scientific Advisory Board | 5.7yrs | no data | no data | |
| Member of the Scientific Advisory Board | 1.3yrs | no data | no data | |
| Member of the Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | 1.7yrs | €42.50k | 0.037% € 117.7k | |
| Member of the Scientific Advisory Board | 1.3yrs | no data | no data | |
| Member of the Scientific Advisory Board | 1.3yrs | no data | no data |
Experienced Board: 4FR's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 13:28 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Faron Pharmaceuticals Oy is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Carnegie Commissioned Research |
| Jason Kolbert | D. Boral Capital LLC. |
| Patrick Trucchio | H.C. Wainwright & Co. |